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In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral 
bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated 
for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by 
scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized 
formulation (FT5) was compared with marketed immediate release formulation (Atorva®) in rabbits. 
Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low 
polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive 
values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility 
of AVST with excipient used in the formulations. In vitro release study showed that the drug release was 
sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic 
parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation 
(Atorva®). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST 
in rabbit model.
Uniterms: Atorvastatin calcium/oral bioavailability/experimental study. Atorvastatin calcium/in vitro 
release. Atorvastatin calcium/pharmacokinetics. Nanoparticles/drugs bioavailability.
No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para 
melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de 
evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial 
zeta, a liberação in vitro e a morfologia da superfície, por meio da microscopia eletrônica de varredura 
(MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a 
formulação comercial, de liberação imediata, comercializada (Atorva®), em coelhos. O tamanho das das 
nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade 
(PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 
13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de 
AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação 
sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações 
significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação 
à comercializada (Atorva® ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da 
biodisponibilidade oral de AVST em coelhos.
Uniterms: Atorvastatina cálcica/biodisponibilidade oral/estudo experimental. Atorvastatina cálcica/
liberação in vitro. Atorvastatina cálcica/farmacocinética. Nanopartículas/biodisponibilidade de fármacos.
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INTRODUCTION
Oral ingestion is  the most convenient and 
commonly employed route of drug delivery due to its 
ease of administration, high patient compliance, cost 
effectiveness, least sterility constraints and flexibility in 
the design of dosage form. However, the major problem 
with the design of oral dosage forms lies with their poor 
bioavailability. The oral bioavailability depends on several 
factors including aqueous solubility, drug permeability, 
dissolution rate, first pass metabolism and susceptibility 
to efflux mechanisms. The most frequent causes of low 
bioavailability are attributed to poor solubility and low 
permeability (Yellela, 2010).
Nanoparticles (NP) are a type of colloidal drug 
delivery system comprising particles with a size range from 
10 to 1000 nm in diameter. Nanoparticles may or may not 
exhibit size-related properties that differ significantly from 
those observed in fine particles or bulk materials (Buzea, 
Pacheco, Robbie, 2007). The uptake of nanoparticulate 
systems (NPSs) through the gastrointestinal tract (GIT) 
is today a well-known and accepted phenomenon, 
NPS uptake from the gut can provide an additional 
drug administration route; each system has its own 
pharmacokinetic parameters and specific drug-carrying 
ability. The bioactive molecule is transported into the GIT 
by carriers whose physicochemical characteristics must 
be taken into account, although the physicochemical and 
pharmacological characteristics of the drug remain intact 
(Kreuter, 1991; Hussain, Jaitely, Florence, 2001; Florence, 
Hussain, 2001; Nishioka, Yoshino, 2001; Hans, Lowman, 
2002). 
Peyer’s patches are the most important structural 
units of the gut associated with lymphoid tissue (GALT); 
they are characterized by M-cells that overlie the lymphoid 
tissue and are specialized for endocytosis and transport 
into intraepithelial spaces and adjacent lymphoid tissue. 
Nanoparticles bind to the apical membrane of M-cells, 
after which they are rapidly internalized and “shuttled” to 
the lymphocytes. The lymphatic absorption of a drug via 
the GALT has an advantage over the portal blood route, 
because it avoids presystemic metabolism by the liver 
(hepatic first-pass effect) (Florence, Hussain, 2001; Hans, 
Lowman, 2002).
Nanoparticles were first developed for the parenteral 
route; more recently, they have also been studied as oral 
delivery vehicles. The major interest is in the lymphatic 
uptake of nanoparticles by Peyer’s patches in the GALT 
(Bala, Hariharan, Kumar, 2004). Microparticles remain 
in Peyer’s patches, while nanoparticles are disseminated 
systemically (Hans, Lowman, 2002). Clearly, a wide 
variety of drugs can be delivered via the oral route using 
polymeric nanoparticulate carriers and much of the 
research has focused on the absorption enhancement of 
peptides proteins, and vaccine antigens (Delie, Blanco-
Prieto, 2005).
Mucoadhesive ability can be conferred to NPSs by 
coating their surface with microadhesive polymers such 
as chitosan or Carbopol; action is more effective and 
prolonged, confirming the usefulness of mucoadhesive 
properties (Takeuchi, Yamamoto, Kawashima, 2001). 
Insulin entrapped in PACA nanospheres dispersed in an 
oily phase containing a surfactant produces prolonged 
hypoglycemia (Damge et al., 1997b). The fate of poly 
(isobutylcyanoacrylate) nanocapsules carrying insulin 
administered to rats was monitored by fluorescence and 
transmission electron microscopy (TEM) and evidenced 
intestinal absorption through the epithelial mucosa (Pinto-
Alphandary et al., 2003). A luminescent polymer was 
used as a visible tracer to monitor the oral fate of PLGA 
microspheres containing insulin (Li, Jang, Jin, 2004). The 
therapeutic effects of another peptide, octreotide, can be 
improved and prolonged on incorporation into PACA 
nanocapsules (Damge et al., 1997a).
AVST, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-
4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-
3,5-dihydroxyheptanoic acid, calcium salt (2:1) 
trihydrate, is a BCS class II drug used in the treatment of 
hypercholesterolemia. It is insoluble in aqueous solutions 
at pH 4 and below. It exhibits low oral bioavailability of 
14% which is ascribed to the presystemic clearance in 
the gastrointestinal mucosa and extensive hepatic first 
pass metabolism. It acts by competitive inhibition of 
HMG-CoA reductase, hence; it prevents the conversion 
of HMG-CoA to mevalonate, an early rate-limiting 
step in the biosynthesis of cholesterol (Lennernas, 
2003). 
In this study, we prepared AVST loaded chitosan 
nanoparticles to improve the oral bioavailability of AVST. 
The usefulness of AVST loaded chitosan nanoparticles 
was evaluated by measuring its particle size and surface 
morphology, loading efficiency, drug release profile, 
and pharmacokinetics parameters in rabbits to fully 
characterize the system. 
MATERIAL AND METHODS
Atorvastatin calcium and amlodipine besylate were 
obtained as gift sample from Ozone Pharmaceutical, 
Guwahati, India. Chitosan and Pluronic F68 were procured 
from Balaji drugs, India. All other chemicals and solvents 
used are of analytical grade.
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Drug-excipient compatibility study by FT-IR 
spectroscopy (Ahmed, Nath, 2014)
FT-IR spectra  were  recorded on a  Bruker 
spectrophotometer (Model-220, Germany) using KBr 
discs in the range of 4000-450 cm-1. FT-IR analysis was 
performed using sample of AVST with various excipients 
at 1:1 mass/mass ratio.
Preparation of drug loaded Chitosan 
nanoparticles
AVST loaded chitosan nanoparticles were prepared 
by the emulsion–diffusion–evaporation method (Yadav 
et al., 2012) as per the composition shown in Table I. In 
brief, 10 mg of AVST and 10-50 mg of chitosan (1:1 to 1:5, 
drug to polymer ratio) were dissolved in 20 ml of acetone-
acetic acid mixture (1:2 ratio) at room temperature for 2 h. 
The organic phase was then added to 50 ml of an aqueous 
phase containing Pluronic F68 (4% w/v) as stabilizer. The 
resulting primary o/w emulsion was stirred at 1000 rpm 
for 1 h and subsequently homogenized at 24,000 rpm for 5 
min using a high-speed homogenizer (IKA T25 digital Ultra 
Turrax, Germany). To this emulsion, water was added with 
constant stirring to facilitate diffusion and finally evaporate 
the organic solvent. This resulted in polymer precipitation 
and formation of nanoparticles. Free drug and surfactant 
were separated by centrifuging (REMI cooling centrifuge, 
Vasai) the drug loaded nanoparticles at 10,000×g for 20 min.
Characterization of nanoparticles
Particle size and zeta potential (Patil et al., 2009) 
Hydrodynamic diameter and zeta potential of 
nanoparticles were determined using Zetasizer Nano ZS 90 
dynamic light scattering equipment (Malvern Instruments 
Ltd. UK). Nanoparticles (~1 mg/mL) were dispersed 
in distilled water using sonication prior to particle size 
and zeta potential determinations. Mean hydrodynamic 
diameters were calculated based on size distribution by 
TABLE I - Composition of AVST nanoparticles
F. No. AVST (mg) chitosan (mg) Pluronic F68 (mg) Acetone-acetic acid mixture (1:2 ratio) mL
Distilled water 
(mL)
F1 10 10 2 20 50
F2 10 20 2 20 50
F3 10 30 2 20 50
F4 10 40 2 20 50
F5 10 50 2 20 50
weight, assuming a lognormal distribution, and the results 
were expressed as mean ± S.D. of five runs. Zeta potential 
values were calculated from measured velocities, and 
results were expressed as mean ± S.E.M. of five runs.
Encapsulation efficiency (Zhu et al., 2010)
Loading of AVST in chitosan nanoparticles were 
determined by extracting 5 mg nanoparticles with 1 mL 
acetone for 6 h. From this solution 0.2 mL was diluted 
with phosphate buffer pH 6.8 and analyzed by UV 
spectrophotometer (Shimadzu UV-1800, Japan) at 264 nm 
against appropriate blank. Drug loading and encapsulation 
efficiency were calculated by using equation Eq. (1) and 
Eq. (2) respectively:
             % Drug Loading =
Amount of drug in
nanoparticles (mg)
Amount of
nanoparticles (mg)
 Eq. (1)
  
  
% Entrapment Efciency =
Amount of drug in
nanoparticles (mg)
Initial mount
of drug (mg)
 Eq. (2)
  
In vitro release (Wilson et al., 2008)
Drug release from nanoparticles was determined 
in 0.1 N HCl and phosphate buffer pH 6.8 at 37 °C. 
Nanoparticle suspension (1 mg/mL, 0.5 mL) was placed 
in a dialysis tube (cellulose membrane, Sigma Chemical 
Company, USA) and immersed in 10 mL of the release 
buffer in a 15-mL centrifuge tube and shaken in an 
incubator shaker set at 100 rpm. At predetermined time 
intervals, 1 mL of the buffer solution was removed 
from the tube and analyzed for drug content by UV 
spectrophotometer (Shimadzu UV-1800, Japan) at 264 nm 
against appropriate blank.
Kinetic analysis of the release data
AVST release from nanoparticles was studied 
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by various math ematical models described elsewhere 
(Ghosal; Ray, 2011). These models were applied taking 
into account the amount of drug released from 1 to 48 
hours at different intervals as determined in release 
studies in-vitro. Various equations employed in this study 
were zero-order model; first order model, Higuchi square 
root equation and Korsmeyer–Peppas model due to their 
simplicity and appli cability (Ghosal, et al., 2012; Li, et 
al., 2006).
The mathematical expressions for the semi-empiri-
cal models are as follows:
 Qt = K0t + C0  Eq. (3)
 Qt = KH√t + CH  Eq. (4)
 lnQt = ln Q0 + Kt  Eq. (5)
where Qt is the cumulative percentage amount of drug 
released at time t, Q0 is the initial amount of drug in 
nanoparticles, K0, KH, Kt, are release rate constants, and 
C0, CH are the respective y-intercepts in the absorbance 
vs. time curve. Korsmeyer–Peppas model was used 
specifically to explore release mechanisms and the fraction 
of drug release (Eq. 6) (Korsmeyer et al., 1983).
 (Mt/M∞) = ktn Eq. (6)
where k is a constant incorporating the structural and 
geometric characteristics of the matrix tablets, n is the 
release exponent, indicative of the drug release mechanism 
and (Mt/M∞) represents the drug dissolved fraction at time 
t. To clarify the release exponent for different formulations, 
the log value of the percentage drug released was plotted 
against log time according to Eq. (7). 
 Log (Mt/M∞) = log k + n log t Eq. (7)
During the Korsmeyer–Peppas model fitting, we 
obtained the value of the release exponent n, which 
conveys information on whether the release mechanism 
is Fickian, non-Fickian or case II transport mechanism. 
In this context, n=0.5 indicates Fickian release (diffusion 
controlled release) and n=1 indicates a purely relaxation-
controlled delivery, which is referred to as case II transport. 
When the value of n is intermediate, it indicates an 
anomalous behaviour (non-Fickian kinetics corresponding 
to coupled diffusion/polymer relaxation). A value of n>1 
indicates super case II kinetics.
Scanning electron microscopy (SEM) of nanoparticles
The shape and surface characteristics of the 
nanoparticles were observed by scanning electron 
microscopy (SEM). The nanoparticle sample was thinly 
sprinkled onto a metal stub and vacuum coated with 
a thin layer of gold in an argon atmosphere. The SEM 
photomicrographs of the coated particles were obtained 
at 15 kV using a ZEISS, Germany, scanning electron 
microscope (Thangaraja, Savitha, Jegatheesan, 2010).
Pharmacokinetics studies
The study was carr ied out  to compare the 
pharmacokinetics parameters of AVST from a prepared 
nano formulation (F5) to a conventional commercially 
available immediate release tablet formulation (Atorva®, 
10) following oral administration of doses 2.4 mg/kg in 
two groups of animals (five in each group). The study 
was approved by Institutional Animal Ethics Committee 
of Girijananda Chowdhury Institute of Pharmaceutical 
Science; vide no. 1372/c/10/CPCSEA.
The animals used for study were male albino rabbits 
weighing about 1.5-2 kg, obtained from Animal House 
of Girijananda Chowdhury Institute of Pharmaceutical 
Science, Guwahati, India. The animals were kept under 
standard laboratory conditions at a temperature of 
25 ± 2 °C and relative humidity (55 ± 5%). The animals 
were divided into two groups as Group-I and Group-II. 
Each rabbit of Group- I was given marketed formulation 
dose (2.4 mg/kg) according to their weight using oral 
feeding needle. Same dose of nanoparticle suspension was 
administered to Group-II animals. About 0.5 mL of blood 
samples were collected from orbital sinus at interval of 0.5, 
1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hr into microfuse 
tube containing 15 µL Sodium Citrate (3.3% w/v) solution 
for each sample and centrifuged at 5000 rpm for 15 min 
at 4 ºC to separate plasma. The separated plasma samples 
were frozen at -20 ºC till analysis.
Plasma sample analysis
Then 200 µL of each plasma sample was taken into 
a 5 mL centrifuge tube and 50 µL of amlodipine besylate 
(AMDP) solution (50 µg/mL) was added as an internal 
standard (IS) and the mixtures were vortexed for 30 s. 
After that, 2 mL acetonitrile was added into the mixture, 
vortexed for additional 2 min and centrifuged at 10,000 rpm 
for 10 min. The supernatant was transferred into a glass 
centrifuge tube and evaporated to dryness at 45 ºC under 
a stream of nitrogen. The residue was reconstituted 
with 200 µL of reconstitution solvent (mobile phase).
The samples were filtered through 0.45 µm membrane 
filter using syringe filter. An aliquot of 20 µL of the 
sample was injected onto the HPLC column for analysis. 
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The HPLC system consisted of a Dual pump, (Model 
M515, Waters corp., USA) and UV-Visible detector 
(Model M2489, Waters corp., USA) set at a wavelength of 
264 nm. The samples were chromatographed on a reverse 
phase NOVA-PAK HR C18 column (4 µm, 150 × 3.9 mm, 
Ireland). The mobile phase consisting of acetonitrile and 
0.05 M ammonium acetate solution in the ratio of 45:55 
(v/v) with an apparent pH 6.09 was filtered through a 
0.45 µm membrane filter and degassed under vacuum 
before use. It was pumped at a flow rate of 1.5 mL/min for 
the run time of 10 min under these experimental conditions 
with an injection volume of 20 µL of the sample solution 
(Rheodyne Injector, Model 7725i) (Waters corp. USA). 
The amount of drug present in 200 µL of plasma [(quantity 
obtained from regression equation/200) x 1000)] was 
calculated.
Extraction efficiency and validation of bio-
analytical methods 
For recovery of drug from plasma different organic 
extraction solvents (ethyl acetate, acetonitrile and methanol) 
were tried in the experiment and acetonitrile was proved 
to be the most efficient in extracting AVST from rabbit 
plasma and had a small variation in extraction recoveries 
over the concentration range. Spiked plasma sample was 
prepared in triplicate at single concentration of 30 µg/mL 
of AVST and 50 µg/mL of IS, and assayed as described 
above. The extraction efficiency of AVST was determined 
by com- paring the peak areas measured after analysis 
of spiked plasma sample with those found after direct 
injection of non-biological (unextracted) samples into the 
chromatographic system at the same concentration levels.
The bio-analytical method was validated for 
specificity, recovery, linearity and precision. The 
specificity of the method was determined by comparing 
the chromatograms obtained from the solution of AVST 
and IS with those from blank plasma. Linearity of the 
calibration curve was determined by taking nine different 
concentrations (0.2 -50 µg/mL) of AVST with fixed 
concentration of IS (50 µg/mL) in blank plasma. The 
calibration curve was plotted between the ratio of peak 
areas of AVST to IS and concentration of AVST. Both 
repeatability (within a day precision) and reproducibility 
(between days precision) were determined. Four 
quality control samples were subjected for the study. 
Five injections of each of the specified quality control 
samples were injected for analysis within the same 
day for repeatability, and over a period of 5 days for 
reproducibility. The relative standard deviations (RSD) 
and percent coefficient of variation (%CV) were calculated 
and used to predict the precision of the method.
Determination of pharmacokinetics parameters
The pharmacokinetic parameters were determined 
from the data of plasma drug concentration at different 
time points by using MS-Excel 2003 software according 
to the procedure described elsewhere (Jambhekar, Breen, 
2009; Bourne, 2001).
Data and statistical analysis
Data are represented as mean ± SD (n=5). Statistical 
comparisons were made using one-way analysis of 
variance (ANOVA). A value of p<0.05 was considered 
statistically significant. All data processing was performed 
using the SPSS® statistical software program (SPSS® 14, 
Microsoft, USA).
RESULTS AND DISCUSSION
FT-IR analysis of drug–excipients mixture
FT-IR spectroscopy study was carried out to test the 
compatibility of AVST with chitosan and Pluronic F68 
used as polymer and stabilizer in the formulation. FT-IR 
spectra of AVST showed presence of characteristics band 
at 3362 cm-1for (-OH), 3236 cm-1 for (-NH), 2971 cm-1 
for (-CH3), 2824 cm-1 for (-CH aromatic), 1649 cm-1 for 
(C=O), 1578 cm-1 for (C-N), and 1432 cm-1 for (C-C) 
functional groups. All these characteristics bands were 
also retained in 1:1 physical mixture of AVST-chitosan and 
AVST-Pluronic F68 showed in Figure 1. The results clearly 
revealed the incompatibility of drug with the excipients 
used in the formulation.
FIGURE 1 - FT-IR spectra of AVST (A), chitosan (B) and 1:1 
physical mixture of AVST and chitosan (C).
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Physico-chemical characterization of AVST 
loaded nanoparticles
The Physico-chemical characteristics of AVST-
loaded chitosan nanoparticles were summarized in Table 
II. The result showed the high yield of nanoparticle i.e. 
66.66±0.73 to 85.71±0.68%. The average loading of 
AVST in nanoparticles were about 4±1.1%, 9±1.0%, 
13±0.92%, 15±0.93%, 16±0.80% and encapsulation 
efficiency of 8.02±2.2%, 25.2 ± 2.8%, 48.10 ± 3.4%, 
72.02 ± 4.5%, 96.01 ± 4.8% in formulation F1, F2, F3, F4, 
F5 respectively. The average loading and encapsulation 
efficiency in the formulations were found to be increase 
with increase in polymer concentration used in the 
formulations. A maximum of 16 ± 0.80% drug loading 
and 96.01±4.8% entrapment efficiency was observed 
at 1:5, drug to polymer ratio in formulation F5, the 
change in drug loading may be due to the poor aqueous 
solubility and high binding capacity of drug on polymer 
surface in organic solvent used in the nanoparticle 
formulation.
The result showed the average size of prepared 
nanoparticles varied from 179.3±7.12 to 256.8±8.24 nm 
with a polydispersity index (PI) in the range of 
0.461±0.002 to 0.252±0.004 as shown in Table II. 
Size of nanoparticle was increased with increase in 
polymer concentration. Nevertheless, the PI was found 
to be always lower than 0.5, which is considered as an 
evidence of a homogeneous nanoparticle formulation. 
On the other hand, in all the AVST-loaded nanoparticles 
formulations had zeta potential value of 13.03±0.32 
to 46.9±0.49 mV. The net positive surface charge 
of all formulations may be due to the use cationic 
polyelectrolyte (chitosan) and the addition of Pluronic 
F68 in the formulation aids to reduce aggregation of 
nanoparticles may results the stability of the formulations. 
The average droplet of the selected formulation F5 by 
dynamic light scattering determination was 46.9±0.49 mV 
(Figure 2).
TABLE II - Physico-chemical characterization of AVST-loaded chitosan nanoparticles
F. No. D:Pol ratio Size(nm) ZetaPotential (mV) Yield (%) EE (%) PI
F1 1:1 179.3 ± 7.12 13.03 ± 0.32 66.66 ± 0.73 8.02 ± 2.2 0.461 ± 0.002
F2 1:2 201.2 ± 8.23 19.77 ± 0.45 70.01 ± 0.70 25.20 ± 2.8 0.318 ± 0.012
F3 1:3 227.8 ± 5.19 23.10 ± 0.58 74.02 ± 0.68 48.10 ± 3.4 0.326 ± 0.015
F4 1:4 238.9 ± 9.21 29.16 ± 0.43 80.10 ± 0.75 72.02 ± 4.5 0.283 ± 0.008
F5 1:5 256.8 ± 8.24 46.90 ± 0.49 85.71± 0.68 96.01 ± 4.8 0.252 ± 0.004
Data expressed as the mean ± SD (n=3). EE: Encapsulation efficiency PI: Polydispersity Index D: Pol (Drug: Polymer).
FIGURE 2-AVERAGE zeta potential of the formulation F5 
containing 1:5 ratio of drug to polymer measured by dynamic 
light scattering method.
FIGURE 3 - In vitro drug release profile for different formulations 
in 0.1 N HCl.
In vitro drug release studies
In vitro release profiles of AVST loaded chitosan 
nanoparticles in 0.1N Hydrochloric acid and Phosphate 
buffer pH 6.8 are shown in Figure 3 and Figure 4 
respectively. Sustained release of drug was observed from 
the formulations in 0.1N Hydrochloric acid and Phosphate 
buffer pH 6.8 for duration 48 hours. It was found that as 
the concentration of polymer increased in the formulations 
drug release was sustained for longer period, which may be 
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TABLE III - Comparative release kinetics parameter of all the batches of nanoparticles
F. No.
Release kinetic parameter
Zero order First order Higuchi Korsmeyer and Peppas
R0 K0 RF KF RH KH RP nP
F1 0.8659 1.68 0.7257 0.019 0.8679 14.470 0.9571 0.7950
F2 0.8603 1.04 0.7302 0.020 0.8346 9.193 0.9636 0.8165
F3 0.8646 0.9821 0.7285 0.018 0.8710 7.942 0.9591 0.7239
F4 0.8662 0.9247 0.7852 0.016 0.8684 8.5322 0.9651 0.7456
F5 0.8763 0.8455 0.7400 0.022 0.9149 6.933 0.9828 0.8766
FIGURE 4 - In vitro drug release profile for different formulations 
in Phosphate buffer pH 6.8.
due to the hydration ability of chitosan, which on coming 
in contact with dissolution media leads to the formation of 
gelatinous mass and act as retardant material for the drug to 
diffuse out. Thus a prolonged release of drug is attained and 
at the end of 48 hours, the cumulative % drug release from 
formulations F1, F2, F3, F4, F5 was 95.04±0.48, 64.6±0.52, 
58.94±0.56, 52.54±0.52, 44.62±0.32 in 0.1N Hydrochloric 
acid and 95.24±0.38, 94.6±0.44, 88.54±0.54, 82.1±0.54, 
74.12±0.28 in Phosphate buffer pH 6.8 respectively. Thus 
F5 formulation contained higher percentage of polymer 
(1:5, Drug: polymer ratio) was able to sustain the release 
of drug for long period of time (more than 48 h) compared 
to other formulations in 0.1 N hydrochloric acid medium.
Kinetics and mechanism of drug release
The in vitro drug release data was fitted into 
appropriate equations, the correlation coefficient (R) and 
the release rate constant was determined from the slope of 
the respective equations for all formulations (Table III). 
Among all the formulations F5 found to be best fitted in 
Higuchi kinetics with RH value of 0.9149, followed by zero 
order (RO=0.8763) and first order (RF=0.7400) kinetics. 
This explains that drug release from the nanoparticle 
formulations followed primarily diffusion controlled 
release mechanism. Further, to confirm the drug release 
mechanism from the nanoparticle formulations the in 
vitro drug release data at various time points were fitted 
into the Korsemayer-Peppas equation. The correlation 
coefficient (Rp values) of 0.9571, 0.9636, 0.9591, 0.9651 
and 0.9828 for the formulations F1, F2, F3, F4 and F5 
respectively which showed good linearity between log 
cumulative amount of drug release versus log time, and 
the highest linearity was observed with F5, where drug to 
polymer concentration was maximum (1:5). The release 
exponents (nP values) were found to be 0.7950, 0.8165, 
0.7239, 0.7456 and 0.8766 for the formulations F1, F2, 
F3, F4 and F5 respectively. The obtained nP values of all 
the formulations were greater than 0.5 and less than 1. 
Hence, it is revealed that the mechanism of drug release 
was a non-Fickian or anomalous diffusion.
Surface morphology
Particle images obtained by SEM from F5 samples, 
as shown in Figure 5, indicated that produced nanoparticles 
were spherical in shape with smooth surface and the 
size of particles varied from 212.3 nm to 230.9 nm. No 
agglomeration and uniformly distribution of the particles 
confirmed the stability of formulation. Magnification of 
a single particle showed the internal cage like structure 
where the drug molecules are dispersed uniformly 
throughout the polymer matrix. The drug appeared as 
white spots on the surface. It was observed that when 
a high energy electron beam were passed to scan the 
particles in SEM, the polymer burns out leaving the drug 
particles viewed as a cage like structure.
Extraction efficiency and bio-analytical methods
The recovery of drug was found to be 91.25% ± 3.03, 
82.37% ± 2.07 and 77.28 ± 1.72 (w/w) in acetonitrile, ethyl 
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acetate and methanol respectively at all three concentration 
levels, which confirmed the extraction efficiency of 
the solvents. Among the solvents, acetonitrile showed 
maximum amount of drug recovery. Hence, acetonitrile 
was selected as the extracting solvent. The recovery of IS 
was also found to be maximum in acetonitrile which was 
96.23% ± 2.2 (w/w).
Under the described conditions of the bio-analytical 
methods, the retention time of AVST and AMDP was 
found 3.0 and 2.2 min respectively (Figure 6). Absence of 
the interfering peaks near the retention time of the AVST 
as well as IS indicating the specificity of the method. 
The chromatographic responses (ratio of peak area of 
AVST to IS versus AVST concentration) were found to 
be linear over an analytical range of 0.2–50 µg/mL with 
regression coefficient value of 0.9977, which showed 
reproducibility. The relative standard deviation (RSD) and 
percent coefficient of variation (%CV) of intra-day assay 
of the drug was ranged from 0.0098 to 0.0326 and 0.98 to 
3.26%; for the inter-day assay was from 0.0049 to 0.0297 
and 0.49 to 2.97% respectively (Table IV). The low RSD 
and % CV indicate the precision of the method. 
Pharmacokinetics parameters
The comparison of the different pharmacokinetic 
parameters was done by using a one-way analysis of 
variance (ANOVA). A value of p<0.05 was considered 
statistically significant. The pharmacokinetics parameters 
were derived from plasma drug concentrations versus 
time profile of all the subjects and the results are shown 
in Table V and Figure 7. From the pharmacokinetic 
study, it can be revealed that the optimised nanoparticle 
formulation, F5 showed better Cmax, Tmax and AUC than the 
marketed formulation (Atorva®) of drug. It was found that 
the Cmax in plasma for optimised nanoparticle formulation 
(219.78 μg/mL) represents greater improvement than 
the marketed formulations (103.3 μg/mL). It was 
also observed that AUC0-48h of optimised nanoparticle 
formulation was 2618.98 μg.hr/mL and thus the difference 
were highly significant (p<0.05) as compared to AUC0-48h 
of marketed tablet suspension (Table IV) formulation. 
The tmax of optimised nanoparticle formulation was 
FIGURE 5 - SEM image of particles from F5 formulation 
(A) Nanoparticles in spherical shape with smooth surface. 
(B) Magnification of a single particle showed the internal cage 
like structure of size 212.3 to 238.9 nm.
TABLE IV - Precision and accuracy of method for the estimation of AVST in rabbit plasma
Concentration 
(µg/mL)
Intra-day precision Inter-day precision
Mean ± SD (n = 5)  
(µg/mL) RSD %CV
Mean ± SD (n = 5)  
(µg/mL) RSD %CV
0.2 0.1988+0.0065 0.0326 3.26 0.1982+0.0059 0.0297 2.97
10 10.116+0.2060 0.0203 2.03 10.04+0.0894 0.0089 0.89
30 29.974+0.2962 0.0098 0.98 29.992+0.1392 0.0049 0.49
50 49.962+0.8064 0.0161 1.61 50.252+0.6157 0.0122 1.22
SD-Standard deviation, RSD-Relative Standard Deviation, CV-Coefficient of Variation
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TABLE V – Pharmacokinetic parameters
Parameters Units Marketed formulation(Atorva
®) 
Mean ± SD (n = 5)
Optimised formulation, F5 
Mean ± SD (n = 5)
Cmax μg/mL 103.3 ± 1.22 219.78 ± 2.54
Tmax Hrs 2 ± 0.24 2 ± 0.08
AUC0-48h μg-hr/mL 1232.84 ± 2.66 2618.98 ± 2.98
FIGURE 6 - HPLC chromatogram of AVST and internal standard (AMDP) in rabbit plasma.
FIGURE 7 - Plasma concentration profiles of optimized 
formulation (F5) and marketed formulation (Atorva®) after oral 
administration in rabbits (mean ± SD, n = 5).
found to be similar when compared to tmax of marketed 
tablet suspension. The difference in Cmax of optimised 
nanoparticle formulation was very significant (p<0.05) 
when compared with the marketed tablet suspesion. It 
was also observed that AUC0-48h of optimised nanoparticle 
formulation was nearly 2.2 fold increase in the AUC for 
the nanoparticles as opposed to the pure drug (Atorva®). 
Furthermore, this result suggested the iprovement of oral 
absorption of AVST in nanoparticle formulation, which 
may be due to the changes in gastrointestinal membrane 
permeability of the drug and the inhibition of an apically 
polarized efflux system.
CONCLUSION
In conclusion stable nanoparticles with positive zeta 
potential value between 13.03±0.32 to 46.90±0.49 mV and 
particle size range between 179.3 ± 7.12 to 256.8±8.24 nm 
of calcium atorvastatin was prepared successfully using 
solvent evaporation techniques. Nanoparticle size depends 
primarily on the excess of polymer added into the system 
and in vitro release study revealed the sustained release of 
drug for 48h. Results of pharmacokinetics study showed a 
significant difference in the pharmacokinetics parameter 
(2.2 fold increase in AUC) of the optimized formulation 
as compared to marketed formulation (Atorva®). Thus, the 
developed nanoparticles evidenced the improvement of 
oral bioavailability of calcium atorvastatin in rabbit model.
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